Glioblastoma Multiforme grant opportunity – GBM AGILE

Posted: 3 October 2021
Minimum data is due by: 16 February 2022

The objective of the 2021 GBM AGILE Grant Opportunity is to provide a grant of financial assistance to support an Australian medical research and medical innovation project that aims to improve outcomes for Australians diagnosed with brain cancer, specifically Glioblastoma Multiforme (GBM), by leading, co-ordinating and managing the implementation and evaluation of the Australian arm of the GBM AGILE clinical trial.

The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by:

  • improving the health, wellbeing and survival outcomes of Australians with a diagnosis of GBM by providing access to a world-first, innovative clinical trial for a disease where there are few other treatment or trial options; and
  • further build Australia’s clinical trials capacity and infrastructure, thereby supporting future research activities and collaborations.

This grant opportunity is being administered by NHMRC on behalf of the Australian Government Department of Health.

Click here for further information


News & opinion

Member Directory